About Chugai
Chugai’s mission is
to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Mar 14, 2024 Chugai Files New Drug Application in Japan for Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma
- Mar 14, 2024 Chugai Files for Additional Indication of Tecentriq for the Treatment of Alveolar Soft Part Sarcoma, an Ultra-rare Disease
- Mar 11, 2024 Chugai Selected as “Health & Productivity Stock” for the First Time
- Mar 11, 2024 Galderma Announces Nemolizumab Data at American Academy of Dermatology (AAD) Annual Meeting
- Feb 29, 2024 Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors